Astellas Pharma Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALPMY Over the counter 2830 www.astellas.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Astellas Pharma Inc.

New Strong Sell Stocks for August 6th - Aug 6th, 2026 2:30 am
Pfizer (PFE) Announces FDA Approval of PADCEV plus Keytruda in MIBC - Jul 15th, 2026 8:24 am
Pfizer Poised for Mixed Second Quarter, RBC Says - Jul 10th, 2026 10:34 am
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility - Jul 10th, 2026 9:23 am
Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor - Jun 24th, 2026 2:12 am
Sector Update: Healthcare Stocks Advance in Afternoon Trading - Jun 23rd, 2026 11:38 am
Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas - Jun 23rd, 2026 6:05 am
Is Astellas Pharma (ALPMY) Stock Undervalued Right Now? - Jun 22nd, 2026 7:40 am
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year? - Jun 22nd, 2026 7:40 am
Astellas Pharma (TSE:4503) Stock Valuation After KRAS Trial Progress And AI Overhaul - Jun 13th, 2026 10:11 am
Astellas taps AI to reshape clinical programs as rising stars emerge - Jun 12th, 2026 3:21 am
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026? - Jun 11th, 2026 7:38 am
Is Astellas Pharma (ALPMY) a Great Value Stock Right Now? - Jun 5th, 2026 7:40 am
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year? - Jun 5th, 2026 7:40 am
Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data? - Jun 3rd, 2026 9:39 am
Astellas Board Change Raises Questions On R&D Oversight And Governance - Jun 3rd, 2026 4:07 am
Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine - May 26th, 2026 4:16 am
Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company - May 26th, 2026 12:45 am
MRK Stock Gains After CHMP Backs Keytruda Combo for Bladder Cancer - May 25th, 2026 10:25 am
Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony. - May 22nd, 2026 3:20 pm